Leiomyosarcoma (LMS) of the inferior vena cava (IVC) represents 90% of inferior vena cava tumours. It has a poor prognosis. We present three LMS of infrarenal IVC. Survival was long in two patients in spite of a non-radical resection. Chemotherapy and repeat surgery was performed for recurrence. The third patient was in complete remission at last follow-up at 29 months. Mainstay treatment for this tumour is surgical resection. Rescue surgery for local and metastastic recurrences together with systemic chemotherapy and radiotherapy may improve survival.
Article info
Publication history
Published online: July 09, 2007
Identification
Copyright
© 2007 Published by Elsevier Inc.
User license
Elsevier user license | How you can reuse 
Elsevier's open access license policy
Elsevier user license
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy
ScienceDirect
Access this article on ScienceDirectLinked Article
- Leiomyosarcoma of the Infrarenal Inferior Vena Cava: Management in Three Cases and a Review of the LiteratureEJVES ExtraVol. 14Issue 2
- PreviewLeiomyosarcoma (LMS) of the inferior vena cava (IVC) represents 90% of inferior vena cava tumours. It has a poor prognosis. We present three LMS of infrarenal IVC. Survival was long in two patients in spite of a non-radical resection. Chemotherapy and repeat surgery was performed for recurrence. The third patient was in complete remission at last follow-up at 29 months. Mainstay treatment for this tumour is surgical resection. Rescue surgery for local and metastastic recurrences together with systemic chemotherapy and radiotherapy may improve survival.
- Full-Text
- Preview
Related Articles
Comments
Commenting Guidelines
To submit a comment for a journal article, please use the space above and note the following:
- We will review submitted comments as soon as possible, striving for within two business days.
- This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
- We require that commenters identify themselves with names and affiliations.
- Comments must be in compliance with our Terms & Conditions.
- Comments are not peer-reviewed.
